Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Réanimation traumatologique avec du sang total ou des produits à faible titre du groupe O (TROOP)

18 septembre 2026 mis à jour par: Jan O. Jansen, University of Alabama at Birmingham

The goal of this clinical trial is to compare the effectiveness of unseparated whole blood (referred to as Low-Titer Group O Whole Blood) and the separate components of whole blood (including red cells, plasma, platelets, and cryoprecipitate) in critically injured patients who require large-volume blood transfusions.

Aperçu de l'étude

Statut

Complété

Description détaillée

Trauma is one of the leading causes of death in the United States, and disproportionately affects the young, killing those who might otherwise have lived long and productive lives. Injuries account for more years of potential life lost before age 75 than any other cause. Hemorrhage remains the most common cause of preventable death after injury, and blood transfusion is an essential part of treatment. Modern blood banking practices separate donated whole blood into components. The current standard of care in trauma transfusion is the balanced administration of equal numbers of units of blood components (packed red blood cells, plasma, and platelets), effectively attempting to reconstitute whole blood. A renewed approach to blood transfusion therapy in trauma is to use whole blood from the outset, which has not been separated. Compared with component therapy, whole blood offers several potential advantages, but there are only a small number of, mostly observational, studies comparing whole blood and component therapy, and they are very heterogeneous.

The TROOP trial will include injured adults with hemorrhagic shock anticipated to require massive blood transfusions, who will be randomized to receive either whole blood (LTOWB) or blood components. This will allow a direct comparison to see if one type of transfusion is more strongly associated with improved clinical outcomes over the other.

The knowledge gained from this clinical trial will transform the way in which massively bleeding trauma patients are transfused. The trial is exceedingly well positioned to improve mortality from trauma and reduce the number of preventable deaths resulting from hemorrhagic shock.

Type d'étude

Interventionnel

Inscription (Réel)

1100

Phase

  • Phase 3

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Alabama
      • Birmingham, Alabama, États-Unis, 35294
        • University of Alabama at Birmingham, UAB Hospital
    • California
      • Los Angeles, California, États-Unis, 90033
        • Los Angeles County + University of Southern California (LAC + USC) Medical Center
    • Louisiana
      • New Orleans, Louisiana, États-Unis, 70112
        • University Medical Center New Orleans LCMC Health
    • Maryland
      • Baltimore, Maryland, États-Unis, 21201
        • University of Maryland Medical Center
    • Missouri
      • St Louis, Missouri, États-Unis, 63110
        • Washington University School of Medicine
    • North Carolina
      • Winston-Salem, North Carolina, États-Unis, 27157
        • Atrium Health Wake Forest Baptist
    • Ohio
      • Cincinnati, Ohio, États-Unis, 45267
        • University of Cincinnati Medical Center
    • Oregon
      • Portland, Oregon, États-Unis, 97239
        • Oregon Health and Sciences University Hospital
    • Pennsylvania
      • Philadelphia, Pennsylvania, États-Unis, 19104
        • Penn Presbyterian Medical Center
    • Texas
      • Houston, Texas, États-Unis, 77030
        • University of Texas Health Science Center Houston
      • San Antonio, Texas, États-Unis, 78229
        • University of Texas Health San Antonio and University Health System
    • Washington
      • Seattle, Washington, États-Unis, 98104
        • Harborview Medical Center
    • Wisconsin
      • Milwaukee, Wisconsin, États-Unis, 53226
        • Froedtert Hospital

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

15 ans et plus (Enfant, Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  1. Adult trauma patient (estimated age > 15 or weight > 50 kg, if age unknown)

  2. Patient taken to trauma center directly from scene

  3. Commencement of blood transfusion (PRBC, plasma or LTOWB), in pre-hospital or in-hospital setting

  4. Activation of site-specific Massive Hemorrhage Protocol or Massive Transfusion Protocol

  5. Traumatic injury with at least one of the following:

    1. Confirmed or suspected acute major bleeding
    2. Assessment of Blood Consumption (ABC) Score ≥2

Exclusion Criteria:

  1. Patients who have received, prehospital or in-hospital more than two units of LTOWB; the equivalent in components (two units of packed red blood cells and two units of plasma); or a combination of the two (more than one unit of LTOWB, one unit of packed cells, and one unit of plasma). Most trauma centers hold two units of either packed red blood cells (with two units of plasma) or two units of LTOWB in the emergency department. This stock is used to initiate transfusion, while the massive hemorrhage protocol is activated from the blood bank.
  2. Patients transferred from another hospital
  3. Children <15 years (in most communities, patients aged 15-18 years are treated at adult trauma centers, and patients in this age group frequently suffer life-threatening injuries, and will therefore be included)
  4. Known prisoners, defined as individuals involuntarily confined or detained in a penal institution (including juvenile detention, involuntary psychiatric commitment, or court-ordered residential substance abuse treatment)
  5. Moribund patients expected to die within 1 hour
  6. Patients who required an ED thoracotomy or received more than 5 consecutive minutes of cardiopulmonary resuscitation (prior to receiving randomized blood products)
  7. Patients with known "do not resuscitate" orders prior to randomization
  8. Patients who refuse the administration of blood products
  9. Individuals with a research "opt out" bracelet.
  10. Greater than 20% total body surface area (TBSA) burns
  11. Suspected inhalation injury victims
  12. Patients who are obviously pregnant on clinical examination or known to be pregnant as provided by the subject or legally authorized representative

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Double

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Comparateur actif: LTOWB

Participants randomized to receive (Low Titer O Whole Blood [LTOWB])

Participants will receive Low Titer O Whole Blood administered intravenously or intraosseously.

Comparateur actif: Components

Participants randomized to receive the component blood products.

Participants will receive separated blood components (i.e., units of red cells, plasma, platelets, and cryoprecipitate) co-administered intravenously or intraosseously.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
6-hour Mortality
Délai: First 6 hours after randomization

Participant vital status at 6-hours following randomization (randomization defined as product container is opened for administration to participant)

First 6 hours after randomization

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
24-hour Mortality
Délai: First 24 hours after randomization

Participant vital status at 24-hours following randomization

First 24 hours after randomization
Hospital/30-day Mortality
Délai: From randomization to hospital discharge or 30-days post randomization (whichever the earlier)

Participant vital status at hospital discharge or 30-days post randomization (whichever the earlier)

From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
Incidence of Pre-specified Complications
Délai: From randomization to hospital discharge or 30-days post randomization (whichever the earlier)

The number of participants experiencing pre-specified complications. Pre-specified complications include: Acute kidney injury; Ventilator-associated pneumonia; Multiorgan failure; Transfusion-related hyperkalemia; Transfusion-related hypocalcemia; Transfusion associated circulatory overload; Acute respiratory distress syndrome; Symptomatic and asymptomatic deep vein thrombosis; Symptomatic and asymptomatic pulmonary embolism; Bleeding after hemostasis requiring intervention; Stroke; Myocardial infarction; Abdominal compartment syndrome; Transfusion-related allergic reactions; Febrile non-hemolytic transfusion reaction; Systemic inflammatory response syndrome; Sepsis; Alloimmunization in women of childbearing age

From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
Adjudicated Primary Cause of Death
Délai: 30-days post randomization

Primary cause of death as reviewed and determined by the study investigators (consensus)

30-days post randomization
Length of Stay (Hospital and Intensive Care Unit)
Délai: From randomization to hospital discharge or 30-days post randomization (whichever the earlier)

Number of hours hospitalized (includes both hospital and intensive care unit time)

From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
Hospital-, Ventilator- and Intensive Care Unit-free days
Délai: 30-days post randomization

Number of days participant was alive and out of the hospital; number of days participant was not on a ventilator; and the number of days the participant was not in the intensive care unit.

30-days post randomization
Incidence of major surgical procedures
Délai: From randomization to hospital discharge or 30-days post randomization (whichever the earlier)

The proportion of participants undergoing major surgical procedures.

From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
Time to hemostasis in those undergoing procedures with a hemostatic component
Délai: From randomization to hospital discharge or 30-days post randomization (whichever the earlier)

Time to hemostasis refers to the time that the subject achieved hemorrhage control (anatomic hemostasis and resuscitation complete) following emergency department arrival.

From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
Number and type of blood products used until hemostasis is achieved and from hemostasis to 24 hours after randomization
Délai: First 24 hours after randomization

The number of units and type of blood products (e.g. whole blood, packed red blood cells, platelets, plasma, etc.)

First 24 hours after randomization
Discharge destination
Délai: At hospital discharge or 30-days post randomization (whichever the earlier)

Discharge destination will be measured as a categorical variable. Categories will be tallied and compared between the two study arms. Example variables include: discharged to home, discharged to another primary care facility, discharged to hospice, etc.

At hospital discharge or 30-days post randomization (whichever the earlier)
Functional status
Délai: From randomization to hospital discharge or 30-days post randomization (whichever the earlier)

Functional status will be measured by Extended Glasgow Outcome Scale (GOSE). The GOSE is a tool used to measure recovery following brain injury and assists with prediction of long-term rehabilitation. The 8 scoring categories are death, vegetative state, lower severe disability, upper severe disability, lower moderate disability, upper moderate disability, lower good recovery and upper good recovery. A higher GOSE score correlates with better outcome.

From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
Patient's quality of life
Délai: From randomization to hospital discharge or 30-days post randomization (whichever the earlier)

Quality of life will be measured by the Euroqol Group's EQ-5D quality of life measurement. The EQ-5D is a patient-reported questionnaire assessing health status in terms of five dimensions of health (mobility, self-care, usual activities, pain and discomfort, and anxiety and depression). Lower EQ-5D scores are associated with better outcome.

From randomization to hospital discharge or 30-days post randomization (whichever the earlier)

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Jan Jansen, MBBS, PhD, University of Alabama at Birmingham

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

27 juillet 2023

Achèvement primaire (Réel)

4 août 2026

Achèvement de l'étude (Réel)

4 août 2026

Dates d'inscription aux études

Première soumission

8 novembre 2022

Première soumission répondant aux critères de contrôle qualité

28 novembre 2022

Première publication (Réel)

6 décembre 2022

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

22 septembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

18 septembre 2026

Dernière vérification

1 août 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • IRB-300010517
  • 1UG3HL157401-01A1 (Subvention/contrat des NIH des États-Unis)
  • 1U24HL157310-01A1 (Subvention/contrat des NIH des États-Unis)

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner